Gyre Therapeutics raises $20M in public offering for Phase 2 F351 trial

GYRE THERAPEUTICS, INC.

Issued 2,222,222 shares at $9.00/share; underwriters have 30-day option for 333,333 additional shares.
Net proceeds estimated at $18.5M after discounts and expenses.
Funds U.S. Phase 2 trial of F351 in MASH-associated liver fibrosis, R&D, and working capital.
Offering expected to close May 27, 2025; Jefferies LLC is sole book-running manager.

item 1.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.